Lambert C.,University of Liège |
Dubuc J.-E.,Cliniques Universitaires Saint Luc |
Montell E.,Bioiberica |
Verges J.,Bioiberica |
And 3 more authors.
Arthritis and Rheumatology | Year: 2014
Objective To compare the gene expression patterns of synovial cells from inflamed or normal/reactive areas of synovial membrane obtained from the same patient with osteoarthritis (OA). Methods At the time of total knee replacement, synovial tissues were obtained from 12 patients with knee OA. The inflammation status of the synovial membrane was characterized according to macroscopic criteria and classified as normal/reactive or inflamed. Biopsy samples were cultured separately for 7 days. Microarray gene expression profiling was performed on normal/reactive and inflamed areas. Western blot and immunohistochemistry were used to confirm the identified genes that were differentially expressed. Results We identified 896 genes that were differentially expressed between normal/reactive and inflamed areas. The key pathways were related to inflammation, cartilage metabolism, Wnt signaling, and angiogenesis. In the inflammation network, the genes TREM1 and S100A9 were strongly up-regulated. The genes MMP3, MMP9, CTSH (cathepsin H), and CTSS (cathepsin S) were significantly up-regulated in the cartilage catabolism pathway, while the most up-regulated anabolism enzyme gene was HAS1. In the Wnt signaling pathway, the genes for Wnt-5a and low-density lipoprotein receptor-related protein 5 were up-regulated, while the gene FZD2 and the gene for Dkk-3 were down-regulated. Finally, STC1, which codes for a protein involved in angiogenesis, was identified as the most up-regulated gene in inflamed compared with normal/reactive areas. Conclusion This study is the first to identify different expression patterns between 2 areas of the synovial membrane from the same patient. These differences concern several key pathways involved in OA pathogenesis. This analysis also provides information regarding new genes and proteins as potential targets of treatment. © 2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.
Bioiberica | Date: 2013-08-16
Chemical products for stabilizing foodstuffs; Chemical preparations for preserving foodstuffs; chemical products for use in the pharmaceutical, nutraceutical, infant nutrition, medical nutrition and functional food industries, namely, chemical substances for use in the manufacture of pharmaceuticals, nutraceutical, infant nutrition, medical nutrition and functional food products; all of the foregoing containing Omega-3. Pharmaceutical products for the treatment of joint pain, osteoarthritis, dry skin, psychiatric disorders, alzheimers, cognitive health; for use in dermatology or for as an anticoagulant; chemico-pharmaceutical products for the treatment of joint pain, osteoarthritis, dry skin, psychiatric disorders, alzheimers, cognitive health; for use in dermatology or for as an anticoagulant; and for treatment of cardiovascular and vascular diseases; chemical products for pharmaceutical purposes, namely, medicated polymer-based preparations for the treatment of cardiovascular and vascular diseases; chemical products for pharmaceutical and neutraceutical use, namely, nutritional supplements; dietary and nutritional supplements; pharmaceutical products; dietetic substances for medical use, namely, diet capsules and diet pills, food supplements for medical use, mineral food supplements and food supplements based on amino acids, glycosaminoglycans, minerals, vitamins and/or trace elements; dietetic foods for medical use, namely, dietetic fiber; all the aforesaid goods in galenic form as powders, capsules, pills or liquids, all exclusively for human consumption and comprising omega fatty acids. Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits and vegetables; fruit jellies, jams, compotes; eggs; milk and dairy products excluding ice cream, ice milk and frozen yogurt; edible oils and fats; all of the above made in whole or part of Omega-3.
Bioiberica | Date: 2012-12-04
Bioiberica | Date: 2015-09-07
Native, not denatured collagen used as a raw ingredient in the manufacture of food and supplements for use in the food and pharmaceutical industry for health relating to joints.
Bioiberica | Date: 2014-05-21
Chemical products for use in industry, science, photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; soil fertilizers; fire extinguishing compositions; tempering and soldering preparations; chemicals for preserving foodstuffs; tanning substances; adhesives for use in industry. Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruit and vegetables; jellies, jams, compotes; eggs, milk and dairy products; edible oils and fats. Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages and juices; syrups and other preparations for making beverages.
Bioiberica | Date: 2012-04-12
Publications, namely, leaflets, booklets and teaching materials in the field of the health of the joints.
Bioiberica | Date: 2011-10-20
Bioiberica | Date: 2012-10-11
Medicines for medical use and anti-inflammatory and anti-rheumatic pharmaceutical products; dietetic supplements, food supplements for medical use, all the aforesaid goods based on mucopolysaccharides for improving joint health in general, tendon and ligament health, joint mobility, flexibility and for use as a treatment combined with other treatments for osteoarthritis.
Bioiberica | Date: 2013-07-30
Bioiberica | Date: 2011-08-29
Dietary and nutritional supplements.